Strong growth of NextPlat Corp. (NASDAQ: NXPL) featured on the Proactive Podcast

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, appeared in an interview with Proactive, where its CEO Charlie Fernandez joined host Steve Darling to provide an update on the company’s latest financial results. NextPlat has made impressive progress in consolidating its global e-commerce and Progressive Care healthcare operations, which has led to significant growth. During the interview, Fernandez highlighted the company’s strong financial results in the third quarter, reporting consolidated revenues of $15.3 million. This represents a remarkable increase of over 481% compared to the third quarter of the previous year. Additionally, the company’s gross margin saw significant improvement, reaching 30% in the quarter ending September 30, 2023, compared to the previously reported 26%. These financial results demonstrate NextPlat’s successful consolidation efforts and its ability to generate revenue and improve profitability. The company is well-positioned to continue its success and deliver value to its stakeholders as it continues to grow its business and explore new opportunities in the e-commerce and healthcare sectors.

To view the full article, visit https://ibn.fm/d0wZ6

About NextPlat Corp.

NextPlat is a global e-commerce platform designed to tap into a wide range of rapidly growing sectors and markets, including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company aims to help businesses sell goods online, domestically and internationally, enabling customers and partners to optimize their e-commerce presence and revenues. NextPlat currently operates an e-commerce communications division offering voice, data, tracking and IoT products and services globally, as well as pharmaceutical and healthcare data management services in the United States.

NOTE FOR INVESTORS: For the latest news and updates on NXPL, visit the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform focusing on the latest developments in the biotechnology (BioTech), biomedical sciences (BioMed) and life sciences sectors. It is one of over 60 brands on the market Dynamic brand portfolio @ INB it delivers: : (1) access to an extensive network of wired solutions through InvestorWire to efficiently and effectively reach countless target markets, demographic groups and diverse industries; (2) distribution of articles and editorials to over 5,000 outlets; (3) improved press release refinement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full range of customized corporate communications solutions. With its broad reach and experienced team of journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide range of investors, influencers, consumers, journalists and the general public. By cutting through the information overload in today’s marketplace, BMW provides its customers with unrivaled brand recognition and awareness.

BMW is where breaking news, insightful content and useful information converge.

To receive text alerts from BioMedWire, “Biotech” at 888-902-4192 (US mobile phones only)

More information can be found at https://www.BioMedWire.com

Please read the full terms of use and disclaimers on the BioMedWire website that apply to all content provided by BMW, regardless of where it is published or republished: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]